Our IR－Messages to Investors and Future Growth Strategy

SBC Medical Group Holdings, Inc. is the Japan’s largest operator of aesthetic medicine group, originated from Shonan Beauty Clinic. We interviewed the CEO, Mr. Yoshiyuki Aikawa to learn about the company’s changes and initiatives following its listing on the U.S. NASDAQ stock exchange in September 2024, as well as its future prospects.

 

Japan’s first medical group listed on the U.S. NASDAQ

Since the CEO Mr. Aikawa founded Shonan Beauty Clinic in 2000 in his hometown of Fujisawa City, Kanagawa Prefecture, under the belief of “Making Cosmetic Medicine More Accessible”, SBC Medical Holdings (hereafter SBC) has been providing advanced aesthetic medicine for 25 years. Meanwhile, in its efforts to diversify business, the clinic also expanded into general medical fields other than aesthetic medicine, including dermatology, orthopedics, dentistry, AGA treatment (hair loss treatment), gynecology, fertility treatment, ophthalmology, and regenerative medicine. Today, it has grown into one of the Japan’s largest medical groups, with an extensive network of 259 clinics both in Japan and abroad.

In September 2024, SBC became the first Japanese medical group to be listed on the U.S. NASDAQ. Mr. Aikawa explained the background as follows: “Our goal is to be Japan’s No. 1 medical group by 2035 and the world’s No. 1 by 2050, chosen by customers around the globe. I believed enhancing our fundraising capabilities and listing in the U.S.—a country with the world’s largest financial and capital markets, and a global leader in aesthetic medicine—would be the shortest path to achieving our goal.”

In addition, in June 2025, nine months after its listing, SBC was added as a member of the broad-market Russell 3000®Index. “I was both proud and surprised. I believe this is proof that we have been fully recognized as a U.S.-listed company. However, this is only the first step. I want to aim even higher,” said Mr. Aikawa.

 

One year after its listing: where SBC stands in its overseas business strategy

In November 2024, following its NASDAQ listing and as the first step toward becoming the world’s No. 1 medical group, SBC acquired Aesthetic Healthcare Holdings (hereafter AHH), which operates 4 brands and 21 clinics specializing in aesthetic medicine in Singapore. Mr. Aikawa explained: “The Asian aesthetic medicine market holds the second largest share in the world and it is growing significantly compared to other regions, with an average growth rate of 11%*. Among them, we view Singapore as a hub of the Asian market both geographically and culturally, and I want to make our acquisition of AHH, a very popular brand in the country, our first step toward expanding the presence of SBC in the Asian market.

Mr. Aikawa also intends to expand SBC’s business into neighboring countries from Singapore. “In May 2025, we established SBC MEDICAL APAC as a subsidiary, functioning as a hub for the Southeast Asian market. Going forward, we plan to strategically expand our services to other Asian countries, such as Malaysia, Indonesia, Vietnam, Thailand, and Philippines, in order to lay the foundation for establishing SBC’s presence as a global medical group.”

 

The future of SBC: a leader in Japanese aesthetic medicine

On the other hand, regarding their goal of becoming the medical group chosen by the largest number of customers in Japan, what is his vision for the group’s future growth? Mr. Aikawa says: “Fortunately, our group has continued to grow since its foundation at an average rate of 120% each year, and now we serve 6.3 million customers annually and has become the top runner in Japanese aesthetic medicine industry. In recent years, Japanese people have shown increasing interest in aesthetic medicine, with a steady rise in its utilization rate. However, looking at the industry’s situation, there are even more new entrants, intensifying competition. We do hear about issues related to treatments, and we understand some people have anxieties about aesthetic medicine. Under these circumstances, in order to continue securing and expanding our market share, we need to put our customer-first management approach into practice and continue providing services that meet customers’ expectations. Specifically, in the fast-growing field of cosmetic dermatology, by promoting our muti-brand strategy, we aim to introduce treatments that provide higher efficacy to customers and improve convenience, delivering tailored solutions that precisely meet each customer’s needs. In the field of cosmetic surgery as well, we aim to continuously develop new technologies supported by our doctors’ high-level expertise to further strengthen our competitiveness. Furthermore, as an industry leader, we aim to continually enhance our environment to ensure safety and peace of mind for our customers. This is why we convey our attitude, “Shonan Beauty’s Promises”, through various media.”

 

In addition, Mr. Aikawa says he is committed to further expanding the Group’s business in the general medical fields. “Many medical institutions in Japan are now facing financial difficulties. We aim to protect community healthcare and employment by applying our business expertise, which integrates both health insurance-based and private medical treatments. I also have a dream of establishing a general hospital with over 300 beds as SBC’s flagship hospital, where top-notch doctors come together to provide better medical care while also training and developing junior residents in the near future. Listing on NASDAQ was part of our strategy to gain flexible fundraising capabilities toward achieving these ambitions and goals. As we have welcomed new colleagues with diverse experiences and perspectives over the past year, through collaboration with our existing members, I believe we can aim for even greater success than ever before.”

 

To reach the largest number of customers worldwide through medical innovation

Mr. Aikawa says he never imagined that SBC would grow to its current size when he founded Shonan Beauty Clinic 25 years ago. “Since our foundation, we have believed in the power of aesthetic medicine to brighten people’s lives and make them happier, and we have made steady efforts to provide safe, reliable, and high-quality medical services while staying attentive to our customers’ needs. Going forward, staying true to our passions for “contributing to the happiness of people around the world through medical care” and “providing everyone who wishes to change with medical services that are easier to choose and more reliable”, we will pursue the realization of “ultimate win-win-win,”—benefiting customers, staff, and society—or “win-win-win-win”, which includes stakeholders now that we are listed on NASDAQ. We will continue to strengthen management support in various medical fields, including aesthetic medicine, and contribute to the broader delivery of sustainable, high-quality medical services. Please look forward to it.

 

【株主・投資家へのメッセージ】

Messages to shareholders and investors

To achieve SBC’s group purpose, “By medical innovation, contribute to improving the “well-being” of people around the world”, we will continue to expand our clinic network and global operations through data-driven management. We would sincerely appreciate your continued support.

【注釈】

*Source: Straits Research, Aesthetic Medicine Market Size, Share & Trends Analysis Report By Procedure Type (Invasive Procedures, Non-Invasive Procedures) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030